INBX Inhibrx Biosciences Inc.

Price (delayed)

$100.33

Market cap

$1.48B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$8.88

Enterprise value

$1.52B

?
Relative Growth: Rel. Growth: 8
Relative Strength: Rel. Strength: 95
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 6

Inhibrx Biosciences is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates. Inhibrx Biosciences utilizes diverse methods of protein engineering to address the specific ...

Highlights
The EPS has grown by 29% YoY but it has contracted by 6% from the previous quarter
The company's net income rose by 16% YoY but it fell by 6% QoQ
Inhibrx Biosciences's equity has shrunk by 177% YoY and by 152% QoQ
Inhibrx Biosciences's gross profit has plunged by 100% from the previous quarter and by 100% YoY

Key stats

What are the main financial stats of INBX

INBX stock price

How has the Inhibrx Biosciences stock price performed over time
Intraday
-9.34%
1 week
-1.41%
1 month
-3.18%
1 year
247.16%
YTD
27%
QTD
5.89%

Financial performance

How have Inhibrx Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$127.81M
Net income
-$138.18M
Gross margin
N/A
Net margin
N/A
Inhibrx Biosciences's gross profit has plunged by 100% from the previous quarter and by 100% YoY
The revenue has shrunk by 100% QoQ and by 100% YoY
INBX's operating income is up by 23% YoY but it is down by 3.9% QoQ
The company's net income rose by 16% YoY but it fell by 6% QoQ

Price vs fundamentals

How does INBX's price correlate with its fundamentals

Growth

What is Inhibrx Biosciences's growth rate over time

Valuation

What is Inhibrx Biosciences stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 29% YoY but it has contracted by 6% from the previous quarter
Inhibrx Biosciences's equity has shrunk by 177% YoY and by 152% QoQ
The revenue has shrunk by 100% QoQ and by 100% YoY

Efficiency

How efficient is Inhibrx Biosciences business performance
Inhibrx Biosciences's ROIC has soared by 77% YoY and by 11% from the previous quarter
The company's return on assets fell by 15% QoQ and by 9% YoY

Dividends

What is INBX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for INBX.

Financial health

How did Inhibrx Biosciences financials performed over time
Inhibrx Biosciences's total assets is 26% lower than its total liabilities
The total liabilities has grown by 44% YoY
Inhibrx Biosciences's total assets has decreased by 27% YoY and by 16% QoQ
Inhibrx Biosciences's equity has shrunk by 177% YoY and by 152% QoQ
The debt has soared by 70% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.